Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08154225 · 1 trial · 4 indications
An AE is defined as any untoward medical event that occurs after a participant receives the investigational drug, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the investigational drug.
| Arm | Type | Description |
|---|---|---|
| several cohorts with the target doses | EXPERIMENTAL | Single and multiple dose cohorts. Part 1: Participants will receive different target doses of PF-08154225 in a single and multiple dose escalation stage to evaluate their safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD). Part 2: Participants will receive different doses of PF-08154225 in an open label single arm setting to evaluate their safety, tolerability, PK, PD and preliminary efficacy. |
| Name | Type | Description |
|---|---|---|
| PF-08154225 | DRUG | immune-modulating agent |
Select Inclusion Criteria 1. At age between 18 and 70 years at Screening. 2. Confirmed diagnosis of RA according to the 2010 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) criteria at Screening, with symptom at least 6 months prior to Screening 3....
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
PF-08154225 is an investigational small molecule being developed for the treatment of Systemic Lupus Erythematosus (SLE). It is also being studied in other autoimmune diseases including Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, and Systemic Sclerosis. The drug is currently in Phase 1 clinical development.
PF-08154225 is being developed by Pfizer, Inc. (NYSE: PFE). The company is currently conducting a Phase 1 clinical trial to evaluate the drug in participants with autoimmune diseases.
PF-08154225 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 study is designed to evaluate the drug in participants with autoimmune diseases.
PF-08154225 is being studied in a Phase 1 clinical trial registered as NCT07782450, titled "A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases." The trial is not yet recruiting and has an estimated enrollment of 54 participants.
The Phase 1 trial for PF-08154225 (NCT07782450) is studying the drug in participants with Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, and Systemic Sclerosis. The trial is open to adults aged 18 years and older and is not yet recruiting participants.